Data from Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i>-Mutant Colorectal Cancer

Abstract

Listen

Translate article

<div>Abstract<p>Although recent clinical trials of BRAF inhibitor combinations have demonstrated improved efficacy in <i>BRAF</i>-mutant colorectal cancer, emergence of acquired resistance limits clinical benefit. Here, we undertook a comprehensive effort to define mechanisms underlying drug resistance with the goal of guiding development of therapeutic strategies to overcome this limitation. We generated a broad panel of <i>BRAF</i>-mutant resistant cell line models across seven different clinically relevant drug combinations. Combinatorial drug treatments were able to abrogate ERK1/2 phosphorylation in parental-sensitive cells, but not in their resistant counterparts, indicating that resistant cells escaped drug treatments through one or more mechanisms leading to biochemical reactivation of the MAPK signaling pathway. Genotyping of resistant cells identified gene amplification of <i>EGFR, KRAS</i>, and mutant <i>BRAF</i>, as well as acquired mutations in <i>KRAS, EGFR</i>, and <i>MAP2K1</i>. These mechanisms were clinically relevant, as we identified emergence of a <i>KRAS</i> G12C mutation and increase of mutant <i>BRAF</i> V600E allele frequency in the circulating tumor DNA of a patient at relapse from combined treatment with BRAF and MEK inhibitors. To identify therapeutic combinations capable of overcoming drug resistance, we performed a systematic assessment of candidate therapies across the panel of resistant cell lines. Independent of the molecular alteration acquired upon drug pressure, most resistant cells retained sensitivity to vertical MAPK pathway suppression when combinations of ERK, BRAF, and EGFR inhibitors were applied. These therapeutic combinations represent promising strategies for future clinical trials in <i>BRAF</i>-mutant colorectal cancer. <i>Cancer Res; 76(15); 4504–15. ©2016 AACR</i>.</p></div>